{"product_id":"anticancer-therapeutics-isbn-9781118622124","title":"Anticancer Therapeutics","description":"\u003cp\u003e\u003cb\u003eAn integrated presentation of the basic science and clinical applications of anticancer agents\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAimed at both undergraduate and postgraduate readers, this unique text provides readers with a fully-integrated presentation of all aspects of the science of anticancer drugs, including their chemistry, pharmacology, and clinical applications.\u003c\/p\u003e \u003cp\u003eAfter heart disease, cancer is the number one killer worldwide, and the tumor microenvironment is forever changing, creating an ever-greater demand for safer, more effective anticancer agents. In response to that demand, the $100 billion cancer drug market continues to grow, with our increased understanding of cancer leading to new drugs being used clinically almost every year.\u003c\/p\u003e \u003cp\u003e\u003ci\u003eAnticancer Therapeutics \u003c\/i\u003eis divided into three sections. Section 1 is an introduction to cancer and therapeutics, and covers the etiology and cellular and molecular basis of cancer. In Section 2, the authors focus on the anticancer agents — their discovery, synthesis, mode of action, mechanisms of resistance, and adverse reactions. Section 3 focuses on specific cancers, explaining how and why the various agents discussed in Section 2 are used, both individually and in combination, to treat different cancers.\u003c\/p\u003e \u003cul\u003e \u003cli\u003eIntegrates aspects of basic science, including chemistry and pharmacology and clinical medicine in relation to cancer therapeutics\u003c\/li\u003e \u003c\/ul\u003e \u003cul\u003e \u003cli\u003eWritten by an author team comprising specialists in medicinal chemistry, pharmacology, and oncology\u003c\/li\u003e \u003cli\u003eFeatures full-color images throughout illustrating how drugs bind to cellular targets and exert their pharmacological effect\u003c\/li\u003e \u003cli\u003eDivided into three sections, covering the etiology and cellular and molecular basis of cancer, anticancer agents, and drug applications for different cancers.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eProviding the reader with an integrated understanding of all aspects of the science of anticancer agents, this is an ideal textbook for undergraduates studying medicine, nursing, medicinal chemistry, pharmacy, pharmacology and other allied heath \/ life sciences. It is also a valuable bench reference for pharmacists, medics, and pharmaceutical researchers working in both academia and industry.\u003c\/p\u003e \u003cp\u003ePreface xi\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 1: Introduction 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1.1 The Global Burden of Cancer 3\u003c\/p\u003e \u003cp\u003eReferences 11\u003c\/p\u003e \u003cp\u003e1.2 Cancer Staging and Classification 13\u003c\/p\u003e \u003cp\u003e1.2.1 Benign Tumour (or neoplasm) 13\u003c\/p\u003e \u003cp\u003e1.2.2 Malignant Tumour (or cancer) 14\u003c\/p\u003e \u003cp\u003e1.2.3 Tumour Nomenclature and Classification 14\u003c\/p\u003e \u003cp\u003e1.2.4 Cellular Differentiation and Tumour Grade 21\u003c\/p\u003e \u003cp\u003e1.2.5 Tumour Invasion and Metastasis 24\u003c\/p\u003e \u003cp\u003e1.2.6 Clinical Staging of Cancer 26\u003c\/p\u003e \u003cp\u003eReferences 36\u003c\/p\u003e \u003cp\u003e1.3 Cellular and Molecular Basis of Cancer 39\u003c\/p\u003e \u003cp\u003e1.3.1 Oncogenes 40\u003c\/p\u003e \u003cp\u003e1.3.2 Tumour Suppressor Genes 45\u003c\/p\u003e \u003cp\u003e1.3.3 Role of Epigenetics and Gene Promoter Regulation in Tumourigenesis 49\u003c\/p\u003e \u003cp\u003e1.3.4 Multistage Tumourigenesis 53\u003c\/p\u003e \u003cp\u003e1.3.5 Oncogene Addiction 54\u003c\/p\u003e \u003cp\u003e1.3.6 Hallmarks of Cancer 55\u003c\/p\u003e \u003cp\u003e1.3.7 Principles of Cancer Treatment 73\u003c\/p\u003e \u003cp\u003eReferences 77\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 2: The Anticancer Agents 81\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e2.1 Agents Which Act Directly on DNA 83\u003c\/p\u003e \u003cp\u003e2.1.1 Nitrogen Mustards and Nitrosoureas 83\u003c\/p\u003e \u003cp\u003eReferences 96\u003c\/p\u003e \u003cp\u003e2.1.2 Temozolomide 98\u003c\/p\u003e \u003cp\u003eReferences 106\u003c\/p\u003e \u003cp\u003e2.1.3 Platinum]containing Agents 108\u003c\/p\u003e \u003cp\u003eReferences 118\u003c\/p\u003e \u003cp\u003e2.1.4 Gemcitabine 120\u003c\/p\u003e \u003cp\u003eReferences 128\u003c\/p\u003e \u003cp\u003e2.1.5 Camptothecin and Its Analogues 128\u003c\/p\u003e \u003cp\u003eReferences 139\u003c\/p\u003e \u003cp\u003e2.1.6 Podophyllotoxins 141\u003c\/p\u003e \u003cp\u003eReferences 150\u003c\/p\u003e \u003cp\u003e2.1.7 Anthracyclines 151\u003c\/p\u003e \u003cp\u003eReferences 160\u003c\/p\u003e \u003cp\u003e2.1.8 Epigenetic Targeting Agents 162\u003c\/p\u003e \u003cp\u003eReferences 177\u003c\/p\u003e \u003cp\u003e2.2 Antimetabolites 181\u003c\/p\u003e \u003cp\u003e2.2.1 Cytarabine 181\u003c\/p\u003e \u003cp\u003eReferences 183\u003c\/p\u003e \u003cp\u003e2.2.2 Methotrexate 184\u003c\/p\u003e \u003cp\u003eReferences 195\u003c\/p\u003e \u003cp\u003e2.2.3 5]Fluorouracil 196\u003c\/p\u003e \u003cp\u003eReferences 205\u003c\/p\u003e \u003cp\u003e2.2.4 6]Mercaptopurine 206\u003c\/p\u003e \u003cp\u003eReferences 210\u003c\/p\u003e \u003cp\u003e2.3 Antimicrotubule Agents 211\u003c\/p\u003e \u003cp\u003e2.3.1 Taxanes 211\u003c\/p\u003e \u003cp\u003eReferences 224\u003c\/p\u003e \u003cp\u003e2.3.2 Vinca Alkaloids 225\u003c\/p\u003e \u003cp\u003eReferences 231\u003c\/p\u003e \u003cp\u003e2.4 Anti]hormonal Agents 233\u003c\/p\u003e \u003cp\u003e2.4.1 Bicalutamide 233\u003c\/p\u003e \u003cp\u003eReferences 239\u003c\/p\u003e \u003cp\u003e2.4.2 Tamoxifen 240\u003c\/p\u003e \u003cp\u003eReferences 247\u003c\/p\u003e \u003cp\u003e2.4.3 Anastrozole 248\u003c\/p\u003e \u003cp\u003eReferences 254\u003c\/p\u003e \u003cp\u003e2.5 Kinase Inhibitors 257\u003c\/p\u003e \u003cp\u003e2.5.1 Discovery 257\u003c\/p\u003e \u003cp\u003e2.5.2 Synthesis 262\u003c\/p\u003e \u003cp\u003e2.5.3 Mode of Action 267\u003c\/p\u003e \u003cp\u003e2.5.4 Mechanism of Resistance 268\u003c\/p\u003e \u003cp\u003e2.5.5 Adverse Drug Reactions 268\u003c\/p\u003e \u003cp\u003eReferences 271\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 3: The Cancers 275\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3.1 Breast Cancer 277\u003c\/p\u003e \u003cp\u003eKey points 277\u003c\/p\u003e \u003cp\u003e3.1.1 Epidemiology 277\u003c\/p\u003e \u003cp\u003e3.1.2 Presentation 279\u003c\/p\u003e \u003cp\u003e3.1.3 Diagnosis 282\u003c\/p\u003e \u003cp\u003e3.1.4 Staging 283\u003c\/p\u003e \u003cp\u003e3.1.5 Treatments 285\u003c\/p\u003e \u003cp\u003eReferences 289\u003c\/p\u003e \u003cp\u003e3.2 Colorectal Cancer 293\u003c\/p\u003e \u003cp\u003eKey points 293\u003c\/p\u003e \u003cp\u003e3.2.1 Epidemiology 293\u003c\/p\u003e \u003cp\u003e3.2.2 Presentation 294\u003c\/p\u003e \u003cp\u003e3.2.3 Diagnosis 296\u003c\/p\u003e \u003cp\u003e3.2.4 Staging 298\u003c\/p\u003e \u003cp\u003e3.2.5 Treatments 299\u003c\/p\u003e \u003cp\u003eReferences 303\u003c\/p\u003e \u003cp\u003e3.3 Leukaemia 307\u003c\/p\u003e \u003cp\u003eKey points 307\u003c\/p\u003e \u003cp\u003e3.3.1 Epidemiology 307\u003c\/p\u003e \u003cp\u003e3.3.2 Presentation 310\u003c\/p\u003e \u003cp\u003e3.3.3 Diagnosis 311\u003c\/p\u003e \u003cp\u003e3.3.4 Staging 313\u003c\/p\u003e \u003cp\u003e3.3.5 Treatments 314\u003c\/p\u003e \u003cp\u003eReferences 319\u003c\/p\u003e \u003cp\u003e3.4 Lung Cancer 323\u003c\/p\u003e \u003cp\u003eKey points 323\u003c\/p\u003e \u003cp\u003e3.4.1 Epidemiology 323\u003c\/p\u003e \u003cp\u003e3.4.2 Presentation 327\u003c\/p\u003e \u003cp\u003e3.4.3 Diagnosis 327\u003c\/p\u003e \u003cp\u003e3.4.4 Staging 330\u003c\/p\u003e \u003cp\u003e3.4.5 Treatments 330\u003c\/p\u003e \u003cp\u003eReferences 337\u003c\/p\u003e \u003cp\u003e3.5 Oesophageal Cancer 339\u003c\/p\u003e \u003cp\u003eKey points 339\u003c\/p\u003e \u003cp\u003e3.5.1 Epidemiology 339\u003c\/p\u003e \u003cp\u003e3.5.2 Presentation 340\u003c\/p\u003e \u003cp\u003e3.5.3 Diagnosis 341\u003c\/p\u003e \u003cp\u003e3.5.4 Staging 344\u003c\/p\u003e \u003cp\u003e3.5.5 Treatments 346\u003c\/p\u003e \u003cp\u003eReferences 350\u003c\/p\u003e \u003cp\u003e3.6 Ovarian Cancer 353\u003c\/p\u003e \u003cp\u003eKey points 353\u003c\/p\u003e \u003cp\u003e3.6.1 Epidemiology 353\u003c\/p\u003e \u003cp\u003e3.6.2 Presentation 354\u003c\/p\u003e \u003cp\u003e3.6.3 Diagnosis 356\u003c\/p\u003e \u003cp\u003e3.6.4 Staging 357\u003c\/p\u003e \u003cp\u003e3.6.5 Treatments 357\u003c\/p\u003e \u003cp\u003eReferences 363\u003c\/p\u003e \u003cp\u003e3.7 Pancreatic Cancer 367\u003c\/p\u003e \u003cp\u003eKey points 367\u003c\/p\u003e \u003cp\u003e3.7.1 Epidemiology 367\u003c\/p\u003e \u003cp\u003e3.7.2 Presentation 368\u003c\/p\u003e \u003cp\u003e3.7.3 Diagnosis 370\u003c\/p\u003e \u003cp\u003e3.7.4 Staging 371\u003c\/p\u003e \u003cp\u003e3.7.5 Treatments 373\u003c\/p\u003e \u003cp\u003eReferences 375\u003c\/p\u003e \u003cp\u003e3.8 Prostate Cancer 379\u003c\/p\u003e \u003cp\u003eKey points 379\u003c\/p\u003e \u003cp\u003e3.8.1 Epidemiology 379\u003c\/p\u003e \u003cp\u003e3.8.2 Presentation 381\u003c\/p\u003e \u003cp\u003e3.8.3 Diagnosis 382\u003c\/p\u003e \u003cp\u003e3.8.4 Staging 384\u003c\/p\u003e \u003cp\u003e3.8.5 Treatments 387\u003c\/p\u003e \u003cp\u003eReferences 391\u003c\/p\u003e \u003cp\u003e3.9 Skin Cancers 393\u003c\/p\u003e \u003cp\u003eKey points 393\u003c\/p\u003e \u003cp\u003e3.9.1 Epidemiology 393\u003c\/p\u003e \u003cp\u003e3.9.2 Presentation 394\u003c\/p\u003e \u003cp\u003e3.9.3 Diagnosis 395\u003c\/p\u003e \u003cp\u003e3.9.4 Staging 396\u003c\/p\u003e \u003cp\u003e3.9.5 Treatments 399\u003c\/p\u003e \u003cp\u003eReferences 403\u003c\/p\u003e \u003cp\u003e3.10 Testicular Cancer 405\u003c\/p\u003e \u003cp\u003eKey points 405\u003c\/p\u003e \u003cp\u003e3.10.1 Epidemiology 405\u003c\/p\u003e \u003cp\u003e3.10.2 Presentation 407\u003c\/p\u003e \u003cp\u003e3.10.3 Diagnosis 407\u003c\/p\u003e \u003cp\u003e3.10.4 Staging 409\u003c\/p\u003e \u003cp\u003e3.10.5 Treatments 409\u003c\/p\u003e \u003cp\u003eReferences 414\u003c\/p\u003e \u003cp\u003eIndex 417\u003c\/p\u003e   \u003cp\u003e\u003cb\u003eAdam Todd, PhD\u003c\/b\u003e is Senior Lecturer in Pharmaceutical Public Health in the School of Pharmacy, Faculty of Medical Sciences, at Newcastle University, UK. He is registered pharmacist, and specializes in oncology and palliative care. \u003c\/p\u003e\u003cp\u003e\u003cb\u003ePaul W. Groundwater, PhD\u003c\/b\u003e is Professor of Medicinal Chemistry in the Faculty of Pharmacy at The University of Sydney, Sydney, Australia. \u003c\/p\u003e\u003cp\u003e\u003cb\u003eJason H. Gill, PhD\u003c\/b\u003e is a Reader in Molecular Therapeutics in the School of Pharmacy, Faculty of Medical Sciences, at Newcastle University, UK.        \u003c\/p\u003e\u003cp\u003e\u003cb\u003eAn integrated presentation of the basic science and clinical applications of anticancer agents\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eAimed at both undergraduate and postgraduate readers, this unique text provides readers with a fully-integrated presentation of all aspects of the science of anticancer drugs, including their chemistry, pharmacology, and clinical applications. \u003c\/p\u003e\u003cp\u003eAfter heart disease, cancer is the number one killer worldwide, and the tumor microenvironment is forever changing, creating an ever-greater demand for safer, more effective anticancer agents. In response to that demand, the $100 billion cancer drug market continues to grow, with our increased understanding of cancer leading to new drugs being used clinically almost every year. \u003c\/p\u003e\u003cp\u003e\u003ci\u003eAnticancer Therapeutics\u003c\/i\u003e is divided into three sections. Section 1 is an introduction to cancer and therapeutics, and covers the etiology and cellular and molecular basis of cancer. In Section 2, the authors focus on the anticancer agents — their discovery, synthesis, mode of action, mechanisms of resistance, and adverse reactions. Section 3 focuses on specific cancers, explaining how and why the various agents discussed in Section 2 are used, both individually and in combination, to treat different cancers. \u003c\/p\u003e\u003cul\u003e \u003cli\u003eIntegrates aspects of basic science, including chemistry and pharmacology and clinical medicine\u003c\/li\u003e \u003cli\u003eWritten by an author team comprising specialists in medicinal chemistry, pharmacology, and oncology\u003c\/li\u003e \u003cli\u003eFeatures full-color images throughout illustrating how drugs bind to cellular tar-gets and exert their pharmacological effect\u003c\/li\u003e \u003cli\u003eDivided into three sections, covering the etiology and cellular and molecular basis of cancer, anticancer agents, and drug applications for different cancers.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eProviding the reader with an integrated understanding of all aspects of the science of anticancer agents, this is an ideal textbook for undergraduates studying medicine, nursing, medicinal chemistry, pharmacy, pharmacology and other allied heath \/ life sciences. It is also a valuable bench reference for pharmacists, medics, and pharmaceutical researchers working in both academia and industry.\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47988745666789,"sku":"NP9781118622124","price":190.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781118622124.jpg?v=1761781424","url":"https:\/\/k12savings.com\/es\/products\/anticancer-therapeutics-isbn-9781118622124","provider":"K12savings","version":"1.0","type":"link"}